维生素D3补充对哮喘合并低维生素D水平儿童严重急性发作的影响:VDKA随机临床试验
VDKA研究为随机双盲安慰剂对照试验,纳入192例6至16岁、使用低剂量吸入性糖皮质激素且血清25-羟基维生素D低于30 ng/mL的哮喘儿童,随机接受维生素D3 4000 IU/d或安慰剂48周。结果显示维生素D3未显著改善至严重急性发作的时间,调整后风险比为1.13(95%CI 0.69-1.85;
要点
- 维生素D3 4000 IU/d未延长哮喘合并低维生素D水平儿童至严重急性发作的时间。
- 两组严重急性发作比例相近:维生素D3组37.5%,安慰剂组34.4%。
- 研究因无效而提前终止,结果不支持用维生素D3预防此类患儿严重急性发作。
核心结论
- 在持续性哮喘且维生素D水平低的儿童中,维生素D3补充相比安慰剂未显著改善至严重哮喘急性发作的时间。
- 研究结果不支持使用维生素D3补充来预防该人群的严重哮喘急性发作。
研究设计与样本
- VDKA研究为随机、双盲、安慰剂对照临床试验,在美国7个中心招募6至16岁哮喘儿童。
- 纳入标准为使用低剂量吸入性糖皮质激素且血清25-羟基维生素D低于30 ng/mL。
- 计划纳入400例,实际随机192例(维生素D3组96例,安慰剂组96例),因无效于2019年3月提前终止。
- 干预为维生素D3 4000 IU/d或安慰剂共48周,并维持丙酸氟替卡松176 μg/d(6-11岁)或220 μg/d(12-16岁)。
主要发现
- 维生素D3组36例(37.5%)和安慰剂组33例(34.4%)发生至少1次严重急性发作。
- 至严重急性发作的平均时间维生素D3组为240天,安慰剂组为253天,平均组间差异-13.1天(95%CI -42.6至16.4)。
- 维生素D3对病毒诱发严重急性发作时间、吸入性糖皮质激素减量比例及累积氟替卡松剂量均无显著改善。
- 严重不良事件两组相似(维生素D3组11例,安慰剂组9例)。
关键数值与推荐
- 维生素D3组严重急性发作比例为37.5%(36/96),安慰剂组为34.4%(33/96)。
- 平均至急性发作时间维生素D3组240天 vs 安慰剂组253天,平均组间差异-13.1天(95%CI -42.6至16.4)。
临床怎么用
- 对于使用低剂量吸入性糖皮质激素且维生素D水平低的持续性哮喘儿童,不应常规补充维生素D3以预防严重急性发作。
- 临床决策应继续以指南推荐的哮喘控制药物为基础,而非依赖维生素D3补充。
局限性
- 研究因无效提前终止,实际样本量192例低于计划的400例。
- 研究人群限定为使用低剂量吸入性糖皮质激素且维生素D低于30 ng/mL的儿童,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Severe asthma exacerbations cause significant morbidity and costs. Whether vitamin D3 supplementation reduces severe childhood asthma exacerbations is unclear. OBJECTIVE: To determine whether vitamin D3 supplementation improves the time to a severe exacerbation in children with asthma and low vitamin D levels. DESIGN, SETTING, AND PARTICIPANTS: The Vitamin D to Prevent Severe Asthma Exacerbations (VDKA) Study was a randomized, double-blind, placebo-controlled clinical trial of vitamin D3 supplementation to improve the time to severe exacerbations in high-risk children with asthma aged 6 to 16 years taking low-dose inhaled corticosteroids and with serum 25-hydroxyvitamin D levels less than 30 ng/mL. Participants were recruited from 7 US centers. Enrollment started in February 2016, with a goal of 400 participants; the trial was terminated early (March 2019) due to futility, and follow-up ended in September 2019. INTERVENTIONS: Participants were randomized to vitamin D3, 4000 IU/d (n = 96), or placebo (n = 96) for 48 weeks and maintained with fluticasone propionate, 176 μg/d (6-11 years old), or 220 μg/d (12-16 years old). MAIN OUTCOMES AND MEASURES: The primary outcome was the time to a severe asthma exacerbation. Secondary outcomes included the time to a viral-induced severe exacerbation, the proportion of participants in whom the dose of inhaled corticosteroid was reduced halfway through the trial, and the cumulative fluticasone dose during the trial. RESULTS: Among 192 randomized participants (mean age, 9.8 years; 77 girls [40%]), 180 (93.8%) completed the trial. A total of 36 participants (37.5%) in the vitamin D3 group and 33 (34.4%) in the placebo group had 1 or more severe exacerbations. Compared with placebo, vitamin D3 supplementation did not significantly improve the time to a severe exacerbation: the mean time to exacerbation was 240 days in the vitamin D3 group vs 253 days in the placebo group (mean group difference, -13.1 days [95% CI, -42.6 to 16.4]; adjusted hazard ratio, 1.13 [95% CI, 0.69 to 1.85]; P = .63). Vitamin D3 supplementation, compared with placebo, likewise did not significantly improve the time to a viral-induced severe exacerbation, the proportion of participants whose dose of inhaled corticosteroid was reduced, or the cumulative fluticasone dose during the trial. Serious adverse events were similar in both groups (vitamin D3 group, n = 11; placebo group, n = 9). CONCLUSIONS AND RELEVANCE: Among children with persistent asthma and low vitamin D levels, vitamin D3 supplementation, compared with placebo, did not significantly improve the time to a severe asthma exacerbation. The findings do not support the use of vitamin D3 supplementation to prevent severe asthma exacerbations in this group of patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02687815.
引用
- Forno E, Bacharier LB, Phipatanakul W, et al. Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial. JAMA. 2020. PMID: 32840597. doi:10.1001/jama.2020.12384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。